Safety, PK & PD of CDR132L in patients with stable heart failure
Research type
Research Study
Full title
Phase I, randomized, double-blind, placebo-controlled study to assess safety, PK and PD parameters of CDR132L in patients with stable heart failure of ischemic origin (NYHA 1- 3)
IRAS ID
263724
Contact name
Jorg Taubel
Contact email
Sponsor organisation
Cardior Pharmaceuticals GmbH
Eudract number
2019-001291-10
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 7 months, 1 days
Research summary
Heart failure is a significant global burden with an estimated prevalence of 40 million patients worldwide, a number that is increasing with the continuous ageing of the population. Heart failure is the most common reason for hospitalisation in Western Societies and the 5-year mortality is greater than many types of cancer (Brauwald 2015). Current treatment focuses on treating symptoms but does nothing to halt the progressing of heart failure. CDR132L is a synthetic antisense oligonucleotide (ASO) which targets the microRNA-132. MicroRNA is directly involved in activating, increasing, decreasing, and down regulating specific genes. This particular microRNA-132 can be abnormally expressed after heart attack and is centrally involved in multiple mechanisms that remodel the heart in heart failure. This remodelling is frequently exaggerated and it is felt that turning off this aberrant mechanism could lead to a normalising of cellular conditions (as was seen in pre-clinical mini-pig trials).\n\nReferences:\nBraunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015 Feb 28;385(9970):812-24.
REC name
London - London Bridge Research Ethics Committee
REC reference
19/LO/0570
Date of REC Opinion
9 May 2019
REC opinion
Favourable Opinion